PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS Real world ischaemic event reduction with PCSK9i mAbs Inclisiran role in plaque stabilisation Discontinuing PCSK9i leads to increased MACE V-MONO trial of inclisiran monotherapy meets primary endpoints

Plasma

Is PCSK9 a marker of early vascular disease?

This study suggests that measurement of PCSK9 could be used as a predictor of early vascular disease in the primary prevention setting. Previous reports have suggested the potential of PCSK9 as a possible biomarker of risk for clinical ischaemic events. This study investigated this in…

Posted on 11 July 2017 | Posted in News

Plasma PCSK9 levels higher in PAD

Atherosclerotic peripheral artery disease (PAD) affects more than 200 million people worldwide (1), and is associated with substantial morbidity. More than 50% of people with PAD have concomitant coronary heart disease, cerebrovascular disease, or both (2). Management of more severe disease is costly; in the…

Posted on 13 July 2016 | Posted in News

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters